You are here

Sarepta Therapeutics

5 of the best paid biopharma CEOs

5 of the best paid biopharma CEOs

PharmaVoice

executive compensation

Sarepta Therapeutics

Flag link:

Sarepta enjoys early sales ramp for DMD gene therapy, maintains confidence in label expansion

Sarepta enjoys early sales ramp for DMD gene therapy, maintains confidence in label expansion

Fierce Pharma

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Sarepta’s disappointing data put the FDA in a difficult spot

Sarepta’s disappointing data put the FDA in a difficult spot

Stat

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Sarepta gene therapy for Duchenne misses main goal of key study

Sarepta gene therapy for Duchenne misses main goal of key study

BioPharma Dive

Sarepta Therapeutics

Duchenne Muscular Dystrophy

clinical trials

Flag link:

6 Drugs Approved Despite Failed Trials or Minimal Data

6 Drugs Approved Despite Failed Trials or Minimal Data

BioSpace

Sarepta Therapeutics

Flag link:

Sarepta offers early look at closely watched gene therapy launch

Sarepta offers early look at closely watched gene therapy launch

BioPharma Dive

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Sarepta sells FDA priority review voucher to mystery buyer for $102M as prices continue to slip

Sarepta sells FDA priority review voucher to mystery buyer for $102M as prices continue to slip

Fierce Pharma

Sarepta Therapeutics

priority review vouchers

Flag link:

Sarepta prices Duchenne gene therapy at $3.2M

Sarepta prices Duchenne gene therapy at $3.2M

BioPharma Dive

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

FDA Approves Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy

FDA Approves Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy

BioSpace

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Biopharma Companies with the Biggest CEO-Employee Pay Gaps

Biopharma Companies with the Biggest CEO-Employee Pay Gaps

BioSpace

executive compensation

Sarepta Therapeutics

Amneal Pharmaceuticals

Charles Rivers Laboratories

Flag link:

FDA delays decision on Duchenne gene therapy and considers narrower approval

FDA delays decision on Duchenne gene therapy and considers narrower approval

BioPharma Dive

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Sarepta Enters Uncharted Territory with Adcomm Approval

Sarepta Enters Uncharted Territory with Adcomm Approval

BioSpace

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

FDA advisers narrowly vote in favor of Sarepta's DMD gene therapy

FDA advisers narrowly vote in favor of Sarepta's DMD gene therapy

Fierce Biotech

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

FDA reviewers flag concerns over Sarepta's gene therapy for DMD

FDA reviewers flag concerns over Sarepta's gene therapy for DMD

Yahoo/Reuters

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Sarepta, days out from critical FDA meeting, lists questions expected at gene therapy AdComm

Sarepta, days out from critical FDA meeting, lists questions expected at gene therapy AdComm

Fierce Biotech

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Go or no go? Sarepta’s gene therapy faces scrutiny

Go or no go? Sarepta’s gene therapy faces scrutiny

EP Vantage

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Pages